Cited 0 times in

Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer

Authors
 Hye Yeon Chon  ;  Hee Seung Lee  ;  You-Na Sung  ;  Yoo Keung Tae  ;  Chan Hee Park  ;  Galam Leem  ;  So Jung Kim  ;  Jung Hyun Jo  ;  Moon Jae Chung  ;  Jeong Youp Park  ;  Seung Woo Park  ;  Seung-Mo Hong  ;  Seungmin Bang 
Citation
 SCIENTIFIC REPORTS, Vol.14(1) : 2942, 2024-02 
Journal Title
SCIENTIFIC REPORTS
Issue Date
2024-02
MeSH
Biomarkers ; Chemotherapy, Adjuvant ; Humans ; Lymphatic Metastasis ; Middle Aged ; Neoplasm Recurrence, Local / pathology ; Pancreatic Neoplasms* / pathology ; Prognosis ; Retrospective Studies
Abstract
To identify risk factors and biomarker for early recurrence in patients diagnosed with pancreatic cancer who undergo curative resection. Early recurrence after curative resection of pancreatic cancer is an obstacle to long-term survival. We retrospectively reviewed 162 patients diagnosed with pancreatic cancer who underwent curative resection. Early recurrence was defined as recurrence within 12 months of surgery. We selected S100A2 as a biomarker and investigated its expression using immunohistochemistry. Of the total, 79.6% (n = 129) of patients received adjuvant chemotherapy after surgery and 117 (72.2%) experienced recurrence, of which 73 (45.1%) experience early recurrence. In multivariate analysis, age < 60 years, presence of lymph node metastasis, and no adjuvant chemotherapy were significantly associated with early recurrence (all P < 0.05). The proportion of patients with high S100A2 expression (H-score > 5) was significantly lower in the early recurrence group (41.5% vs. 63.3%, P = 0.020). The cumulative incidence rate of early recurrence was higher in patients with an S100A2 H-score < 5 (41.5% vs. 63.3%, P = 0.012). The median overall survival of patients with higher S100A2 expression was longer than those with lower S100A2 expression (median 30.1 months vs. 24.2 months, P = 0.003). High-risk factors for early recurrence after surgery for pancreatic cancer include young age, lymph node metastasis, and no adjuvant therapy. Neoadjuvant treatment or intensive adjuvant therapy after surgery may improve the prognosis of patients with high-risk signatures. In patients who receive adjuvant therapy, high S100A2 expression is a good predictor. © The Author(s) 2024.
Files in This Item:
T202402355.pdf Download
DOI
10.1038/s41598-024-52909-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Seung Woo(박승우) ORCID logo https://orcid.org/0000-0001-8230-964X
Park, Jeong Youp(박정엽) ORCID logo https://orcid.org/0000-0003-0110-8606
Bang, Seungmin(방승민) ORCID logo https://orcid.org/0000-0001-5209-8351
Lee, Hee Seung(이희승) ORCID logo https://orcid.org/0000-0002-2825-3160
Chung, Moon Jae(정문재) ORCID logo https://orcid.org/0000-0002-5920-8549
Jo, Jung Hyun(조중현) ORCID logo https://orcid.org/0000-0002-2641-8873
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/199100
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links